Abstract
Objectives
To study the effect of risk minimization measures taken in 2013 for cyproterone acetate/ethinylestradiol
(CPA/EE) on initiation, concomitant use of other hormonal contraceptives (HC) and
potential indications.
Study design
This retrospective study included data on CPA/EE use in 2011–2017 from the Netherlands,
UK, and Italy.
Results
The initiation rate of CPA/EE decreased by 44%–91% between 2011 and 2017. Proportions
with concomitant use of other HC (<3%) and approved indications did not change over
time.
Conclusion
Apart from a strong reduction in CPA/EE use following risk minimization measures,
no major changes were observed regarding concomitant use of other HC or potential
reasons for use.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to ContraceptionAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Hormonal contraception and risk of venous thromboembolism: national follow-up study.BMJ. 2009; 339b2890
- Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–9.BMJ. 2011; 343d6423
- Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives.Lancet. 2001; 358: 1427-1429
European Medicines Agency. Assessment report cyproterone acetate/ethinylestradiol (2 mg/0.035 mg) containing medicinal products. 2013.
EU PAS Register Number EUPAS8412 - Drug Utilization Study on Diane®-35 (and generics) in European healthcare databases. In: European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP).
- Prescribing of cyproterone acetate/ethinylestradiol in UK general practice: a retrospective descriptive study using The Health Improvement Network.Contraception. 2017; 95: 299-305
- Prescription appropriateness of cyproterone acetate/ethinylestradiol in primary care: a population-based study in Italy.Clin Drug Investig. 2017; 37: 755-762
- Thrombotic risk minimization for Diane-35 and generics.Pharmacoepidemiol Drug Saf. 2017; 26: 1411-1417
Article info
Publication history
Published online: May 26, 2020
Accepted:
May 18,
2020
Received:
April 23,
2020
Identification
Copyright
© 2020 Elsevier Inc. All rights reserved.
